Phuturdex › Diseases › Endometrial neoplasm
Drugs in development · updated 30 October 2026
Endometrial neoplasm: drugs in development
As of 30 October 2026 there are 269 active clinical trials (recruiting or ongoing, phases I–III) on 298 drugs for endometrial neoplasm. 168 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 168 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PaclitaxelTaxol, Paxlitaxel | II–III | 46 | NCT05489848 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 46 | NCT07578649 |
| CarboplatinCarboplatine, Paraplatin | II–III | 38 | NCT05489848 |
| Bevacizumabavastin, MVASI | III | 15 | NCT07198074 |
| DostarlimabTSR-042, Jemperli® | III | 14 | NCT07860450 |
| CisplatinCis Platinum, Cisplatine | II–III | 13 | NCT05489848 |
| Letrozoleoral Femara | II–III | 13 | NCT06379113 |
| DoxorubicinAdriamycin, Doxorubincin | III | 10 | NCT06486441 |
| OlaparibAZD2281, Lynparza® | III | 8 | NCT04269200 |
| AtezolizumabTecentriq, MPDL3280A | II–III | 6 | NCT05770102 |
| DurvalumabMEDI4736, Imfinzi® | III | 6 | NCT05255653 |
| Megestrol AcetateMegace Es®, Megace® | II–III | 6 | NCT07319429 |
| DocetaxelTaxotere, Beizray® | III | 5 | NCT06340568 |
| Nab-paclitaxelAbraxane, Nab-placlitaxel | III | 5 | NCT06132958 |
| TrastuzumabHerceptin, tratuzumab | III | 5 | NCT05256225 |
Sorted by most advanced phase and number of active trials. Showing 15 of 130 drugs.
All 298 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Carcinoma, Endometrioid 13 drugs
- Hemangiosarcoma 58 drugs
- Neurofibrosarcoma 24 drugs
- Carcinosarcoma 25 drugs
- Perivascular epithelioid cell neoplasm 5 drugs
- Endometrial stromal sarcoma 3 drugs
- Ovarian neoplasm 411 drugs
- Fallopian tube neoplasm 124 drugs
- Acinar cell carcinoma 5 drugs
- Adenoid cystic carcinoma 26 drugs
- Adrenocortical carcinoma 28 drugs
- Pheochromocytoma 29 drugs
Broader categories
- Female urogenital disease 11 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Genital Diseases, Female 6 drugs
- Genital Diseases 7 drugs
- Uterine disease 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016889 “Endometrial Neoplasms”.